Exelixis
EXEL
#1789
Rank
NZ$19.24 B
Marketcap
NZ$71.50
Share price
1.22%
Change (1 day)
14.39%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Cost to borrow EXEL shares - Exelixis

Latest borrow fee for Exelixis (EXEL) shares on Interactive Brokers: 0.2612% (annualized)

Shares available to borrow: 3300000

The cost to borrow / borrow fee is an annualized percentage an account is charged when borrowing shares of a stock.
Please note that the borrow fee and available shares to borrow displayed on this page are solely based on information provided by Interactive Brokers.

Exelixis (EXEL) - cost to borrow in the last 7 days chart

Exelixis (EXEL) - number of shares available to borrow in the last 7 days

Exelixis (EXEL) - cost to borrow from 2025 to 2023

Exelixis (EXEL) - number of shares available to borrow from 2025 to 2023

Cost to borrow for shares of similar companies or competitors

Company Cost to borrow (% year) Shares available Country
GlaxoSmithKline
GSK
0.4673%1.7 M๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
0.2638%1 M๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
0.2905%10 M๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
0.4081%10 M๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
0.3188%2.7 M๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
0.2868%10 M๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
0.25%10 M๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
0.4244%1.2 M๐Ÿ‡บ๐Ÿ‡ธ USA